Neurogene, Inc./$NGNE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Ticker
$NGNE
Sector
Primary listing
Employees
107
Headquarters
Website
Neurogene, Inc. Metrics
BasicAdvanced
$306M
-
-$4.12
-
-
Price and volume
Market cap
$306M
52-week high
$37.27
52-week low
$6.88
Average daily volume
266K
Financial strength
Current ratio
18.39
Quick ratio
18.101
Long term debt to equity
2.675
Total debt to equity
3.844
Interest coverage (TTM)
-16,218.50%
Profitability
EBITDA (TTM)
-94.208
Management effectiveness
Return on assets (TTM)
-26.91%
Return on equity (TTM)
-42.25%
Valuation
Price to book
1.1
Price to tangible book (TTM)
1.1
Price to free cash flow (TTM)
-5.204
Free cash flow yield (TTM)
-19.21%
Free cash flow per share (TTM)
-3.793
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
1,512.89%
Neurogene, Inc. News
AllArticlesVideos
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Business Wire·4 weeks ago
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Business Wire·1 month ago
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurogene, Inc. stock?
Neurogene, Inc. (NGNE) has a market cap of $306M as of December 11, 2025.
What is the P/E ratio for Neurogene, Inc. stock?
The price to earnings (P/E) ratio for Neurogene, Inc. (NGNE) stock is 0 as of December 11, 2025.
Does Neurogene, Inc. stock pay dividends?
No, Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders as of December 11, 2025.
When is the next Neurogene, Inc. dividend payment date?
Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurogene, Inc.?
Neurogene, Inc. (NGNE) does not currently have a Beta indicator.